Abstract

Retinoblastoma is the commonest intraocular tumor in childhood. Management of retinoblastoma is quite complex depending on the stage, visual and globe saving, psychosocial factors, modality of treatment, and health infrastructure. We report a case of retinoblastoma in a child in a limited health facility without a pediatric oncologist or ophthalmology oncologist. A 22-month old boy came with complaints of leukocoria which his parents had known since the previous week. Ultrasonography of the eye shows calcification on the retina that supports Group E retinoblastoma. Bone marrow aspiration and MRI cannot be performed due to limited resources. Even though the parents only noticed the symptoms for a week and immediately brought to the ophthalmologist, the retinoblastoma stage was already in Group E. Enucleation and globe salvage were unavoidable. Enucleation was performed on the patient with histopathology finding the presence of Flexner-Wintersteiner rosette cells. After enucleation, he was referred to the oncologist for adjuvant chemotherapy. Early retinoblastoma detection is crucial in increasing the cure rate while maintaining children's vision.

There is no Figure or data content available for this article

References

• Ancona-Lezama D, Dalvin LA, Shields CL. Modern treatment of retinoblastoma: A 2020 review. Indian J Ophthalmol. 2020;68(11):2356-2365. doi:10.4103/ijo.IJO_721_20
• Ido Didi Fabian, Ashwin Reddy, Mandeep S Sagoo. Classification and staging of retinoblastoma. Community Eye Health Journal. 2018;31(101):11-13.
• Kivela T. The epidemiological challenge of the most frequent eye cancer: retinoblastoma, an issue of birth and death. British Journal of Ophthalmology. 2009;93(9):1129-1131. doi:10.1136/bjo.2008.150292
• Chawla B, Hasan F, Azad R, et al. Clinical presentation and survival of retinoblastoma in Indian children. British Journal of Ophthalmology. 2016;100(2):172-178. doi:10.1136/bjophthalmol-2015-306672
• Chantada G, Fandino A, Manzitti J, Urrutia L, Schvartzman E. Late diagnosis of retinoblastoma in a developing country. Arch Dis Child. 1999;80(2):171-174. doi:10.1136/adc.80.2.171
• Fabian ID, Abdallah E, Abdullahi SU, et al. Global retinoblastoma presentation and analysis by National Income Level. JAMA Oncol. 2020;6(5):685. doi:10.1001/jamaoncol.2019.6716
• Goddard AG, Kingston JE, Hungerford JL. Delay in diagnosis of retinoblastoma: risk factors and treatment outcome. British Journal of Ophthalmology. 1999;83(12):1320-1323. doi:10.1136/bjo.83.12.1320
• Wong ES, Choy RW, Zhang Y, et al. Global retinoblastoma survival and globe preservation: a systematic review and meta-analysis of associations with socioeconomic and health-care factors. Lancet Glob Health. 2022;10(3):e380-e389. doi:10.1016/S2214-109X(21)00555-6
• Chantada G, Fandino A, Manzitti J, Urrutia L, Schvartzman E. Late diagnosis of retinoblastoma in a developing country. Arch Dis Child. 1999;80(2):171-174. doi:10.1136/adc.80.2.171
• Vempuluru VS, Kaliki S. Screening for retinoblastoma: A systematic review of current strategies. Asia-Pacific Journal of Ophthalmology. 2021;10(2):192-199. doi:10.1097/APO.0000000000000378
• Shields CL, Bas Z, Laiton A, et al. Retinoblastoma: emerging concepts in genetics, global disease burden, chemotherapy outcomes, and psychological impact. Eye. 2023;37(5):815-822. doi:10.1038/s41433-022-01980-0
• Holmes L, Pollack E, Berice BN, et al. Survival disadvantage of male children with retinoblastoma in the United States: Surveillance Epidemiology and End Results (2000–2017) Evidence. Cancer Med. 2023;12(4):4626-4637. doi:10.1002/cam4.3967
• Pearce MS, Parker L. Childhood cancer registrations in the developing world: still more boys than girls. Int J Cancer. 2001;91(3):402-406. doi:10.1002/1097-0215(200002)9999:9999<::aid-ijc1048>3.0.co;2-f
• Dunford A, Weinstock DM, Savova V, et al. Tumor-suppressor genes that escape from X-inactivation contribute to cancer sex bias. Nat Genet. 2017;49(1):10-16. doi:10.1038/ng.3726
• Libert C, Dejager L, Pinheiro I. The X chromosome in immune functions: when a chromosome makes the difference. Nat Rev Immunol. 2010;10(8):594-604. doi:10.1038/nri2815
• Yang YQ, Li J, Yuan HF. Epidemiology and risk factors of retinoblastoma in Chongqing area. Int J Ophthalmol. 2016;9(7):984-988. doi:10.18240/ijo.2016.07.08
• Fabian ID, Sagoo MS. Understanding retinoblastoma: epidemiology and genetics. Community Eye Health. 2018;31(101):7.
• de Graaf P, Göricke S, Rodjan F, et al. Guidelines for imaging retinoblastoma: imaging principles and MRI standardization. Pediatr Radiol. 2012;42(1):2-14. doi:10.1007/s00247-011-2201-5
• Sutton S, Fisher KL. Sonographic Detection of Unilateral Retinoblastoma. Journal of Diagnostic Medical Sonography. 2016;32(4):228-233. doi:10.1177/8756479316650871
• Albader F, Fatani D. Uses of radiological imaging in retinoblastoma. In: Retinoblastoma - Past, Present and Future. IntechOpen; 2019. doi:10.5772/intechopen.86828
• Kaste SC, Jenkins JJ, Pratt CB, Langston JW, Haik BG. Retinoblastoma. American Journal of Roentgenology. 2000;175(2):495-501. doi:10.2214/ajr.175.2.1750495
• Rao AA, Naheedy JH, Chen JYY, Robbins SL, Ramkumar HL. A clinical update and radiologic review of pediatric orbital and ocular tumors. J Oncol. 2013;2013:975908. doi:10.1155/2013/975908
• Ancona-Lezama D, Dalvin L, Shields C. Modern treatment of retinoblastoma: A 2020 review. Indian J Ophthalmol. 2020;68(11):2356. doi:10.4103/ijo.IJO_721_20
• Swathi Kaliki. How to do an enucleation for retinoblastoma. Community Eye Health. 2018;31(101):20-22.
• Daniels AB, Patel SN, Milam RW, Kohanim S, Friedman DL, Koyama T. Effect of intravenous chemotherapy regimen on globe salvage success rates for retinoblastoma based on disease class-A Meta-Analysis. Cancers (Basel). 2021;13(9):2216. doi:10.3390/cancers13092216
• Zhang L, Gao T, Shen Y. Quality of life in children with retinoblastoma after enucleation in China. Pediatr Blood Cancer. 2018;65(7):e27024. doi:10.1002/pbc.27024
• Singh L, Kashyap S. Update on pathology of retinoblastoma. Int J Ophthalmol. 2018;11(12):2011-2016. doi:10.18240/ijo.2018.12.22
• Sari NM, Hadiputri R, Kuntorini MS, Agustina H, Mardianty F. High-Risk histopathologic features of retinoblastoma treated at a tertiary hospital in West Java, Indonesia. Ocul Oncol Pathol. 2021;7(5):353-360. doi:10.1159/000517100
• Honavar SG. Postenucleation adjuvant therapy in High-Risk retinoblastoma. Archives of Ophthalmology. 2002;120(7):923. doi:10.1001/archopht.120.7.923
• Meel R, Radhakrishnan V, Bakhshi S. Current therapy and recent advances in the management of retinoblastoma. Indian Journal of Medical and Paediatric Oncology. 2012;33(02):80-88. doi:10.4103/0971-5851.99731
• Dittner?Moormann S, Reschke M, Abbink FCH, et al. Adjuvant therapy of histopathological risk factors of retinoblastoma in Europe: A survey by the European Retinoblastoma Group (EURbG). Pediatr Blood Cancer. 2021;68(6). doi:10.1002/pbc.28963
• Zhao J, Feng Z, Leung G, Gallie BL. Retinoblastoma survival following primary enucleation by AJCC Staging. Cancers (Basel). 2021;13(24):6240. doi:10.3390/cancers13246240
• Diarra Y, Brockmeyer C, Fischhuber K, et al. Adjuvant therapy for children treated by enucleation at diagnosis of retinoblastoma. EJC Paediatric Oncology. 2023;1:100004. doi:10.1016/j.ejcped.2023.100004
• Yan?k Ö, Gündüz K, Yavuz K, Taçy?ld?z N, Ünal E. Chemotherapy in retinoblastoma: Current Approaches. Turk Oftalmol Derg. 2015;45(6):259-267. doi:10.4274/tjo.06888
• Kaliki S, Shields C. Retinoblastoma: Achieving new standards with methods of chemotherapy. Indian J Ophthalmol. 2015;63(2):103. doi:10.4103/0301-4738.154369
• Tomar AS, Finger PT, Gallie B, et al. Global retinoblastoma treatment outcomes. Ophthalmology. 2021;128(5):740-753. doi:10.1016/j.ophtha.2020.09.032
• Skalet AH, Gombos DS, Gallie BL, et al. Screening children at risk for retinoblastoma. Ophthalmology. 2018;125(3):453-458. doi:10.1016/j.ophtha.2017.09.001
• Lam M, Suh D. Screening, diagnosis, and treatment of pediatric ocular diseases. Children. 2022;9(12):1939. doi:10.3390/children9121939

There is no Supplemental content for this article.

How to Cite This

Article Metrics

Copyright and Permissions

This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.

Publishing your paper with Jurnal Teknologi Laboratorium (JTL) means that the author or authors retain the copyright in the paper. JTL granted an exclusive reuse license by the author(s), but the author(s) are able to put the paper onto a website, distribute it to colleagues, give it to students, use it in your thesis etc, even commercially. The author(s) can reuse the figures and tables and other information contained in their paper published by JTL in future papers or work without having to ask anyone for permission, provided that the figures, tables or other information that is included in the new paper or work properly references the published paper as the source of the figures, tables or other information, and the new paper or work is not direct at private monetary gain or commercial advantage.

JTL journal provides immediate open access to its content on the principle that making research freely available to the public supports a greater global exchange of knowledge. This journal is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License. This license lets others remix, transform, and build upon the material for any purpose, even commercially.

JTL journal Open Access articles are distributed under this Creative Commons Attribution-ShareAlike 4.0 International License (CC BY-SA). Articles can be read and shared for All purposes under the following conditions:

• BY: You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
• SA:  If you remix, transform, or build upon the material, you must distribute your contributions under the same license as the original.

Data Availability